Outlook Therapeutics regains Nasdaq compliance after bid-price cure
Outlook Therapeutics received notice on June 26, 2026 that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after the…
$1.00per share30 consecutive business daysbid price